This research focuses on the development and optimization of an azithromycin nanogel for enhanced dermal delivery in localized skin infections. Azithromycin, a BCS class II macrolide antibiotic, exhibits low aqueous solubility and limited bioavailability, which restrict its therapeutic efficiency when administered orally or topically in conventional forms. A nanosuspension system was formulated,optimized and incorporated into a carbopol-based nanogel to improve skin retention, controlled release, and permeation.The optimized formulation achieved nanoscale particle size (~30 nm), narrow size distribution, and controlled anomalous drug release behavior. Ex vivo permeation studies demonstrated significantly enhanced dermal flux compared with conventional gel, while in vivo skin irritation and antimicrobial studies confirmed dermal safety and efficacy against Staphylococcus aureus and Escherichia coli.
My academic interests focus on the design, optimization, and evaluation of advanced drug delivery systems, particularly nanotechnology-based and vesicular carriers for enhancing bioavailability and therapeutic performance. My research emphasizes transdermal, buccal, sublingual, and nasal delivery platforms as alternatives to conventional oral administration. I am particularly interested in polymer-based controlled release systems, drug–polymer interactions, formulation–performance relationships, and the integration of in vitro, ex vivo, and pharmacokinetic evaluation.
This research focuses on the development and optimization of an azithromycin nanogel for enhanced dermal delivery in localized skin infections. Azithromycin, a BCS class II macrolide antibiotic, exhibits low aqueous solubility and limited bioavailability, which restrict its therapeutic efficiency when administered orally or topically in conventional forms. A nanosuspension system was formulated,optimized and incorporated into a carbopol-based nanogel to improve skin retention, controlled release, and permeation.The optimized formulation achieved nanoscale particle size (~30 nm), narrow size distribution, and controlled anomalous drug release behavior. Ex vivo permeation studies demonstrated significantly enhanced dermal flux compared with conventional gel, while in vivo skin irritation and antimicrobial studies confirmed dermal safety and efficacy against Staphylococcus aureus and Escherichia coli.
My academic interests focus on the design, optimization, and evaluation of advanced drug delivery systems, particularly nanotechnology-based and vesicular carriers for enhancing bioavailability and therapeutic performance. My research emphasizes transdermal, buccal, sublingual, and nasal delivery platforms as alternatives to conventional oral administration. I am particularly interested in polymer-based controlled release systems, drug–polymer interactions, formulation–performance relationships, and the integration of in vitro, ex vivo, and pharmacokinetic evaluation.